Dornase

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 443 publications

Extracellular traps from myeloid cells as therapeutic targets in traumatic heterotopic ossification.

Extracellular traps from myeloid cells as therapeutic targets in traumatic heterotopic ossification.

Journal: Science translational medicine

Published: May 06, 2026

Characterizing Bronchoscopy in Pediatric Critical Care: A Cohort Analysis of Practice and Outcomes.

Characterizing Bronchoscopy in Pediatric Critical Care: A Cohort Analysis of Practice and Outcomes.

Journal: Journal of intensive care medicine

Published: April 09, 2026

Extended Intrapleural Tissue Plasminogen Activator (tPA)-Dornase Alfa (DNase) Therapy Beyond the Standard Multicenter Intrapleural Sepsis Trial 2 (MIST-2) Regimen in a High-Risk Patient With Complex Empyema: A Case Report.

Extended Intrapleural Tissue Plasminogen Activator (tPA)-Dornase Alfa (DNase) Therapy Beyond the Standard Multicenter Intrapleural Sepsis Trial 2 (MIST-2) Regimen in a High-Risk Patient With Complex Empyema: A Case Report.

Journal: Cureus

Published: March 28, 2026

2026 Clinical Practice Guideline Update by the Infectious Diseases Society of America and the Pediatric Infectious Diseases Society on The Management of Community-acquired Pneumonia in Infants and Children Older than 3 Months of Age: The Use of tPa and DNase or tPa Alone for Fibrinolysis.

2026 Clinical Practice Guideline Update by the Infectious Diseases Society of America and the Pediatric Infectious Diseases Society on The Management of Community-acquired Pneumonia in Infants and Children Older than 3 Months of Age: The Use of tPa and DNase or tPa Alone for Fibrinolysis.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: February 27, 2026

Airway Mucosal Defense: Mucins, Innate Immunity, and Contemporary Mucoactive Strategies.

Airway Mucosal Defense: Mucins, Innate Immunity, and Contemporary Mucoactive Strategies.

Journal: Biomedicines

Published: February 17, 2026

Effect of discontinuation and reduction of respiratory cotherapies on the effectiveness of CFTR modulators.

Effect of discontinuation and reduction of respiratory cotherapies on the effectiveness of CFTR modulators.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: February 10, 2026

Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes.

Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 09, 2026

Changes in chronic therapies for cystic fibrosis following initiation of CFTR modulators: A UK retrospective cohort study 2009 - 2023.

Changes in chronic therapies for cystic fibrosis following initiation of CFTR modulators: A UK retrospective cohort study 2009 - 2023.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: February 03, 2026

Infusion of tPA-dornase for management of intraabdominal abscesses: a case report.

Infusion of tPA-dornase for management of intraabdominal abscesses: a case report.

Journal: Journal of surgical case reports

Published: December 07, 2025

Transitioning paediatric empyema management: Comparative efficacy analysis of tPA and DNase versus surgical interventions.

Transitioning paediatric empyema management: Comparative efficacy analysis of tPA and DNase versus surgical interventions.

Journal: Journal of pediatric surgery

Published: October 18, 2025

Therapeutic potential of a long-acting form of rhDNase I for the treatment of cystic fibrosis.

Therapeutic potential of a long-acting form of rhDNase I for the treatment of cystic fibrosis.

Journal: International journal of biological macromolecules

Published: October 16, 2025

Therapeutic potential of a long-acting form of rhDNase I for the treatment of cystic fibrosis.

Therapeutic potential of a long-acting form of rhDNase I for the treatment of cystic fibrosis.

Journal: International journal of biological macromolecules

Published: October 16, 2025

Showing 1-12 of 443

Last Updated: 06/30/2026